Literature DB >> 22072692

The anticonvulsant response to valproate in kindled rats is correlated with its effect on neuronal firing in the substantia nigra pars reticulata: a new mechanism of pharmacoresistance.

Kathrin Töllner1, Saskia Wolf, Wolfgang Löscher, Manuela Gernert.   

Abstract

Resistance to antiepileptic drugs (AEDs) is a major problem in epilepsy treatment. However, mechanisms of resistance are only incompletely understood. We have recently shown that repeated administration of the AED phenytoin allows selecting resistant and responsive rats from the amygdala kindling model of epilepsy, providing a tool to study mechanisms of AED resistance. We now tested whether individual amygdala-kindled rats also differ in their anticonvulsant response to the major AED valproate (VPA) and which mechanism may underlie the different response to VPA. VPA has been proposed to act, at least in part, by reducing spontaneous activity in the substantia nigra pars reticulata (SNr), a main basal ganglia output structure involved in seizure propagation, seizure control, and epilepsy-induced neuroplasticity. Thus, we evaluated whether poor anticonvulsant response to VPA is correlated with low efficacy of VPA on SNr firing rate and pattern in kindled rats. We found (1) that good and poor VPA responders can be selected in kindled rats by repeatedly determining the effect of VPA on the electrographic seizure threshold, and (2) a significant correlation between the anticonvulsant response to VPA in kindled rats and its effect on SNr firing rate and pattern. The less VPA was able to raise seizure threshold, the lower was the VPA-induced reduction of SNr firing rate and the VPA-induced regularity of SNr firing. The data demonstrate for the first time an involvement of the SNr in pharmacoresistant experimental epilepsy and emphasize the relevance of the basal ganglia as target structures for new treatment options.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22072692      PMCID: PMC6633222          DOI: 10.1523/JNEUROSCI.2506-11.2011

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  7 in total

1.  OV329, a novel highly potent γ-aminobutyric acid aminotransferase inactivator, induces pronounced anticonvulsant effects in the pentylenetetrazole seizure threshold test and in amygdala-kindled rats.

Authors:  Malte Feja; Sebastian Meller; Lillian S Deking; Edith Kaczmarek; Matthew J During; Richard B Silverman; Manuela Gernert
Journal:  Epilepsia       Date:  2021-10-07       Impact factor: 5.864

2.  Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease.

Authors:  Ashok Sriram; Herbert E Ward; Anhar Hassan; Sanjay Iyer; Kelly D Foote; Ramon L Rodriguez; Nikolaus R McFarland; Michael S Okun
Journal:  J Neurol       Date:  2012-09-25       Impact factor: 4.849

Review 3.  Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options.

Authors:  Wolfgang Löscher; Heidrun Potschka; Sanjay M Sisodiya; Annamaria Vezzani
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

4.  Interaction of Sodium Valproate With Low-Frequency Electrical Stimulation During Kindlingn.

Authors:  Raha Zalkhani; Ahmad Ali Moazedi; Zohreh Ghotbeddin; Mahdi Pourmahdi
Journal:  Basic Clin Neurosci       Date:  2020-11-01

Review 5.  Bypassing the Blood-Brain Barrier: Direct Intracranial Drug Delivery in Epilepsies.

Authors:  Manuela Gernert; Malte Feja
Journal:  Pharmaceutics       Date:  2020-11-24       Impact factor: 6.321

Review 6.  Drug-induced stuttering: A comprehensive literature review.

Authors:  Naemeh Nikvarz; Salehe Sabouri
Journal:  World J Psychiatry       Date:  2022-02-19

7.  A disinhibitory nigra-parafascicular pathway amplifies seizure in temporal lobe epilepsy.

Authors:  Bin Chen; Cenglin Xu; Yi Wang; Wenkai Lin; Ying Wang; Liying Chen; Heming Cheng; Lingyu Xu; Tingting Hu; Junli Zhao; Ping Dong; Yi Guo; Shihong Zhang; Shuang Wang; Yudong Zhou; Weiwei Hu; Shuming Duan; Zhong Chen
Journal:  Nat Commun       Date:  2020-02-17       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.